Central Nervous System (CNS) | Drug Research, Discovery & Development | Charles River

central nervous system  

 
 

 

CVN Mouse Model for Alzheimer’s Disease Research Studies
A new tool for the study of Alzheimer’s disease, the CVN mouse displays amyloid plaques in the hippocampus at 9 months as well as behavioral and biochemical deficits characteristics of the disease. Learn more...


With an aging population and an increase of central nervous system diseases after the age of 65, there is a mounting need to discover and develop more innovative and effective therapeutic treatments focused on the central nervous system.

Charles River offers a wide range of services supported by our scientific depth, unique technical capabilities and experience in all the major neurodegenerative diseases and neurological indications, such as Alzheimer’s disease, Parkinson’s disease, chronic pain, epilepsy, Multiple Sclerosis, stroke, and more. From animal models of disease to preclinical testing, we have developed the tools to assist clients in shortening the development cycle of compounds with neurological implications. 

Discover the full range of Charles River Products and Services
The Source

For more information, contact us at:

(Country Code)+800.3195.3430
askcharlesriver@crl.com

view all
Cerebricon brings together MRI techniques, biomarkers and behavioral measurements in gold standard assays for acute neurology (e.g., stroke and spinal cord injury), chronic neurology (e.g., multiple sclerosis and Alzheimer’s and Parkinson’s disease) and psychiatry (exemplified by ADHD, schizophrenia and depression).

News & Events

view all
avr. 15 - Putting the 3Rs of Biomedical Res...
avr. 15 - Charles River Signs Partnership A...
juin 22-mai 26 - Tucson, Arizona, United States - Teratology Society Annual Meeting
mai 28-juin 01 - Kobe, Japan - Joint Meering of the International Bone and Mineral Soci...
mai 27-mai 29 - Almere, The Netherlands - Rodent Surgery Hands-on Training (3-day)

Charles River Laboratories, Inc.